HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
Huagongshe Open Program:[email protected]AI access: llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.7.8
  1. Home
  2. /Compound

Doxapram

HCID 3156
NotesReactions
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
309-29-5
Standard SMILES
CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O
InChIKey
XFDJYSQDBULQSI-UHFFFAOYSA-N
Molecular formula
C24H30N2O2
Average molar mass
378.5 g/mol
Monoisotopic mass
378.2307282

Overview

Doxapram is a member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering. It has a role as a central nervous system stimulant. It is a member of morpholines and a member of pyrrolidin-2-ones.

Names & identifiers

Preferred name
Doxapram
IUPAC
1-ethyl-4-(2-morpholin-4-ylethyl)-3,3-diphenylpyrrolidin-2-one
English name
Doxapram
Molecular formula
C24H30N2O2
Molecular weight
378.51

Names & synonyms

doxapram309-29-5DoxapramumDocatone2-Pyrrolidinone, 1-ethyl-4-[2-(4-morpholinyl)ethyl]-3,3-diphenyl-1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone(+-)-doxapram2-Pyrrolidinone, 1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-1-ethyl-4-[2-(morpholin-4-yl)ethyl]-3,3-diphenylpyrrolidin-2-oneCHEBI:6818482-Pyrrolidinone, 1-ethyl-4-(2-(4-morpholinyl)ethyl)-3,3-diphenyl-94F3830Q73
Show more names
ahr619DopramdopreamAHR-619DOXOPRAMRespiramDoxapram USP/EP/BPDOPRAMSTIMULEXRESPIRAMDoxapram (AHR-619, Dopram, Stimulex or Respiram)
DTXSID2022963AHR 6191-ethyl-4-(2-(morpholin-4-yl)ethyl)-3,3-diphenylpyrrolidin-2-oneHydrochloride, DoxapramRefChem:56559DTXCID002963R07AB01206-216-3

Database identifiers

Properties

Computed structural properties

XLogP
3.3
Topological polar surface area
32.8 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
3
Rotatable bonds
6
Heavy atoms
28
Formal charge
0
Complexity
487

Experimental & physicochemical properties

LogP3.6
Solubility · 3 items

Sparingly soluble

WHITE TO OFF-WHITE CRYSTALLINE POWDER; PRACTICALLY INSOL IN ETHER /HYDROCHLORIDE/

3.43e-02 g/L

Human DrugsPharmaceuticals
Melting Point · 2 items

217-219

MP: 123-124 °C /BENZOATE/

Physical DescriptionSolid
Stability/Shelf LifeSTABLE IN LIGHT & IN AIR /HYDROCHLORIDE/
Collision Cross Section · 2 items

183.4 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

185 Ų [M+H]+ [CCS Type: DT; Method: single field calibrated]

Other Experimental PropertiesCRYSTALS FROM ISOPROPYL ETHER; BITTER TASTE; MP: 217-219 °C; SOL IN WATER; SPARINGLY SOL IN ALC; SLIGHTLY SOL IN CHLOROFORM /HYDROCHLORIDE/

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]

P264+P265, P280, P305+P351+P338, and P337+P317 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Hazard information

Hazard Classes and CategoriesEye Irrit. 2 (100%)

Toxicology

Human Toxicity Excerpts...SIDE EFFECTS INDICATIVE OF SUBCONVULSIVE CNS STIMULATION /ARE/... HYPERTENSION, TACHYCARDIA, ARRHYTHMIAS, COUGHING, SNEEZING, VOMITING, ITCHING, TREMORS, MUSCLE RIGIDITY, SWEATING, FLUSHING, & HYPERPYREXIA.
Drug Induced Liver Injury · 5 items

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

doxapram

DILI Negative

Intravenous

DOI:10.1016/j.drudis.2019.09.022

Non-Human Toxicity Excerpts · 1 item

OVERDOSAGE /OF DOXAPRAM TO DOGS/ CAUSED CONSTRICTION OF CEREBRAL VESSELS & REDUCED CEREBRAL BLOOD FLOW & PRODUCED TISSUE ANOXIA SECONDARY TO RESP STIMULATION & LOSS OF CO2. PETECHIAL & PERIVASCULAR HEMORRHAGES WERE FOUND THROUGHOUT BRAIN, BUT...HISTOLOGIC EXAM SHOWED NO ABNORMALITY IN EYES OR OPTIC NERVES. /HYDROCHLORIDE/

Safety data

Signal word
Warning
Symbol(GHS)
GHS07

Chemistry & industry

Pharmacology

ATC Code · 2 items

R - Respiratory system

QR - Respiratory system

Pharmacodynamics · 1 item

Doxapram is an analeptic agent (a stimulant of the central nervous system). The respiratory stimulant action is manifested by an increase in tidal volume associated with a slight increase in respiratory rate. A pressor response may result following doxapram administration. Provided there is no impairment of cardiac function, the pressor effect is more marked in hypovolemic than in normovolemic states. The pressor response is due to the improved cardiac output rather than peripheral vasoconstriction. Following doxapram administration, an increased release of catecholamines has been noted.

Mechanism of Action · 2 items

Doxapram produces respiratory stimulation mediated through the peripheral carotid chemoreceptors. It is thought to stimulate the carotid body by inhibiting certain potassium channels.

DOXAPRAM...STIMULATE ALL LEVELS OF CEREBROSPINAL AXIS. ADEQUATE DOSES PRODUCE TONIC-CLONIC CONVULSIONS SIMILAR IN PATTERN TO THOSE PRODUCED BY PENTYLENETETRAZOL. ...ACT BY ENHANCING EXCITATION RATHER THAN BY BLOCKING CENTRAL INHIBITION.

Biological Half-LifeAFTER IV DOXAPRAM-HCL BOLUS INJECTIONS OR BRIEF INFUSIONS IN HEALTHY VOLUNTEER, PLASMA CONCN DECLINED IN MULTI-EXPONENTIAL FASHION. HALF-LIFE FROM 4-12 HR WAS 3.4.
Metabolism/Metabolites · 2 items

DOXAPRAM YIELDS 4-(2-MORPHOLINOETHYL)-3,3-DIPHENYLPYRROLIDIN-2-ONE, & 1-ETHYL-4-(2-(3-OXOMORPHOLINO)ETHYL)-3,3-DIPHENYLPYRROLIDIN-2-ONE IN DOGS. PITTS, JE, BRUCE, RB, & FOREHAND, JB, XENOBIOTICA, 3, 73 (1973). /FROM TABLE/

AFTER IV DOXAPRAM-HCL BOLUS INJECTIONS OR BRIEF INFUSIONS IN HEALTHY VOLUNTEERS, A METABOLITE AHR 5955 WAS PRESENT IN PLASMA IN AMT COMPARABLE TO PARENT COMPD & HAD A SIMILAR HALF-LIFE.

FDA Pharmacological Classification · 5 items

94F3830Q73

DOXAPRAM

Physiologic Effects [PE] - Increased Medullary Respiratory Drive

Established Pharmacologic Class [EPC] - Respiratory Stimulant

Related reactions

0 records
New reaction record

No reaction records under the current filter.

Compound notes

Loading…

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
CAS
309-29-5
PubChem CID
3156
DTXSID
DTXSID2022963
ChEMBL
CHEMBL1754
ChEBI
CHEBI:681848
UNII
94F3830Q73
EC Number
206-216-3
Nikkaji
J5.501H

Physicochemical properties

Melting point
113 · 113 - 114°C
Boiling point
506.58 °C · 506.58°C (rough estimate)
Density
1.1056 · 1.1056 (rough estimate)
refractive index
1.562 · 1.5620 (estimate)
storage temp.
2 · 2-8°C
solubility
Chloroform (Slightly), Methanol (Slightly)
form
Solid
pka
7.3 · 7.30±0.10(Predicted)
color
White to Off-White
EWG's Food Scores
1 · 1
FDA UNII
94 F3830Q73 · 94F3830Q73
NIST Chemistry Reference
2 · 2-Pyrrolidinone, 1-ethyl-4-[2-(4-morpholinyl)ethyl]-3,3-diphenyl-(309-29-5)
ATC code
7 AB01 · R07AB01
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
317 · H317-H319
Precautionary statements
280 · P280-P305+P351+P338
Hazardous Substances Data
309 · 309-29-5(Hazardous Substances Data)
Hazard statements
H317-H319
Precautionary statements
P280-P305+P351+P338
Hazardous Substances Data
309-29-5(Hazardous Substances Data)

Doxapram is a Respiratory Stimulant. The physiologic effect of doxapram is by means of Increased Medullary Respiratory Drive.

MeSH Pharmacological Classification · 2 items

A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here.

Drugs used for their effects on the respiratory system.

Absorption, Distribution and Excretion · 2 items

AFTER IV DOXAPRAM-HCL BOLUS INJECTIONS OR BRIEF INFUSIONS IN HEALTHY VOLUNTEER, PLASMA CONCN DECLINED IN MULTI-EXPONENTIAL FASHION. VOL OF DISTRIBUTION WAS 1.51 KG-1, & WHOLE BODY CLEARANCE WAS 370 ML MIN-1.

ENTERIC-COATED CAPSULES OF DOXAPRAM WERE ABSORBED RAPIDLY AFTER INITIAL DELAY, & SYSTEMIC AVAILABILITY WAS APPROX 60%. LESS THAN 5% OF AN IV DOSE WAS EXCRETED UNCHANGED IN URINE IN 24 HR.

Cellular LocationsMembrane

Uses & manufacturing

Uses · 2 items

MEDICATION (VET)

MEDICATION

Methods of ManufacturingLUNSFORD, CALE, BELG PATENT 613,734 (1962 TO AH ROBINS), CA 58, 508D (1963); CORRESP TO BRIT PATENT 969,063; LUNSFORD ET AL, J MED CHEM 7, 302 (1964).
Use ClassificationPharmaceuticals
Applications · 3 items

UsesDoxapram HCl inhibits TASK-1, TASK-3, TASK-1/TASK-3 heterodimeric channel function with EC50 of 410 nM, 37 μM, 9 μM, respectively - See more at: http://www.selleckchem.com/products/doxapram-hcl.html#sthash.SSt04Hwr.dpuf

UsesDoxapram increases the rate and depth of respiration. It is used for post-anesthetic respiratory depression, and for respiratory depression caused by drug use.

UsesDoxapram is a central respiratory stimulant.

Upstream & downstream products

Upstream raw materials

DiphenylacetonitrileSulfuric acidHydrochloric acid1-ethyl-3-chloro-pyrrolidineSodium amideMorpholine

Suppliers54 total

武汉英诺医药科技有限公司+86-027-59232304 15387063101 · [email protected]
咸宁深蓝生物医药研发有限公司18171815831 · [email protected]
Suzhou ARTK Medchem Co., Ltd.+86-18168183658 · [email protected]
湖北科乐精细化工有限公司027-59101668 19945030958 · [email protected]
LGM Pharma1-(800)-881-8210 · [email protected]
安耐吉化学&3A(安徽泽升科技有限公司)021-58432009 400-005-6266 · [email protected]
梯希爱(上海)化工贸易有限公司021-61109150 · [email protected]
欧利希(湖北)医药科技有限公司17316404525 17316404525 · [email protected]
InvivoChem中国13549236410 · [email protected]
MedBio脉铂医药021-69568360 18916172912 · [email protected]
銳迪國際科技有限公司18024082417 · [email protected]
上海景颜化工科技有限公司13817811078 · [email protected]
上海泰坦科技股份有限公司4006009262 13023226327 · [email protected]
MedChemexpress LLC021-58955995 · [email protected]
苏州盖德精细材料有限公司0512-66627360 13914021065 · [email protected]
上海陶素生化科技有限公司021-33632979 · [email protected]
泰州同新生物医药科技有限公司0523-86818997 18652728585 · [email protected]
天津普西唐生物医药科技有限公司010-60605840 · [email protected]
江苏艾康生物医药研发有限公司025-66028182 17714375163 · [email protected]
青岛海智微元生物科技有限公司18317699790 18317699790 · [email protected]
上海昕凯医药科技有限公司21-619849051-1 18521059765 · [email protected]
上海陶术生物科技股份有限公司+1-781-999-5354; +1-00000000000 · [email protected]
BOC Sciences16314854226; +8616314854226 · [email protected]
艾吉析科技(上海)有限公司17717235263 17717235263 · [email protected]
上海阿拉丁生化科技股份有限公司6206333 13167063860 · [email protected]
陕西缔都医药化工有限公司029-029-81120477 17792793610 · [email protected]
上海石洋化工有限公司+86-021-56795779 +86-13651600618 · [email protected]
武汉多普乐生物医药有限公司+86-02787215551 19945035818 · [email protected]
上海炎泽化工有限公司15345144255 19901447308 · [email protected]
上海源叶生物科技有限公司18916372613 · [email protected]
上海麦克林生化科技股份有限公司50706066 15221275939 · [email protected]
深圳市创鑫生物科技有限公司13417589054 · [email protected]
武汉沃格达生物科技有限公司15071299552 · [email protected]
上海里程化工有限公司021-67100011 15867680329 · [email protected]
上海泰坦科技股份有限公司13023226327 · [email protected]
杭州洁汉化工有限公司+86-571-86217390; +8618058761490 · [email protected]
Musechem+1-800-259-7612 · [email protected]
河南天孚化工有限公司+86-0371-55170693 +86-19937530512 · [email protected]
career henan chemical co+86-0371-86658258 · [email protected]
广州糖姆氏生命科学有限公司020-31155029 18902330969 · [email protected]
台州市科瑞生物技术有限公司+86-0576-88813233 +86-13396860566 · [email protected]
海蔚化学86-21-51086038 · [email protected]
Aladdin Scientific[email protected]
XIAMEN AMITY INDUSTRY AND TRADE CO., LTD.+8618950047208 · [email protected]
Wuhan Topule Biopharmaceutical Co., Ltd+86-18327326525 · [email protected]
TargetMol中国(陶术生物)4008200310 15002144251 · [email protected]
Alchem Pharmtech,Inc.8485655694 · [email protected]
上海迈瑞尔生化科技有限公司18621169109 · [email protected]
重庆卡兰医药有限公司[email protected]
上海相辉医药科技有限公司13611835272 13611835272 · [email protected]
Additional notes · 1 item

DefinitionChEBI: A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is ubstituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.